Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
2 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Confirm diagnosis as Pompe disease
age 2 years or above
under at least 1 year regular recombinant human acid alpha glucosidase, and no dosage/frequency change in recent 3 months
Provide inform consent
chronic heart disease such as arrhythmia, cardiomyopathy, cardiac infarction
history of seizure
history of diabetes mellitus
history of hyperthyroidism
allergy to β-agonists
under medications including diuretics, digoxin, beta-blockers, etc